1. Home
  2. SNDR vs FOLD Comparison

SNDR vs FOLD Comparison

Compare SNDR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Schneider National Inc.

SNDR

Schneider National Inc.

HOLD

Current Price

$29.49

Market Cap

4.9B

Sector

Industrials

ML Signal

HOLD

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.29

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDR
FOLD
Founded
1935
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.4B
IPO Year
2017
2007

Fundamental Metrics

Financial Performance
Metric
SNDR
FOLD
Price
$29.49
$14.29
Analyst Decision
Buy
Buy
Analyst Count
14
10
Target Price
$28.64
$26.11
AVG Volume (30 Days)
787.2K
10.2M
Earning Date
01-29-2026
02-18-2026
Dividend Yield
1.27%
N/A
EPS Growth
0.60
N/A
EPS
0.64
N/A
Revenue
$5,613,800,000.00
$598,704,000.00
Revenue This Year
$10.44
$21.49
Revenue Next Year
$4.64
$18.46
P/E Ratio
$46.75
N/A
Revenue Growth
5.46
21.28
52 Week Low
$20.11
$5.51
52 Week High
$30.84
$14.38

Technical Indicators

Market Signals
Indicator
SNDR
FOLD
Relative Strength Index (RSI) 60.57 81.20
Support Level $29.44 $14.30
Resistance Level $30.54 $14.36
Average True Range (ATR) 0.70 0.05
MACD -0.05 -0.17
Stochastic Oscillator 61.25 20.83

Price Performance

Historical Comparison
SNDR
FOLD

About SNDR Schneider National Inc.

Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Share on Social Networks: